{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T16:12:28Z","timestamp":1784650348248,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s10637-026-01603-5","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T02:52:17Z","timestamp":1771642337000},"page":"56-63","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A novel aurora kinase molecular glue-based degrader sp-2\u2013067 inhibits prostate cancer cell growth and alters immune profile"],"prefix":"10.1007","volume":"44","author":[{"given":"Sanjeev","family":"Shukla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Pogash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun","family":"Venkatesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"McGrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reynier D. Rodriguez","family":"Rosales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Kanumuambidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Al-Toubat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. C.","family":"Balaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,21]]},"reference":[{"key":"1603_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-025-00817-8","author":"M Hinterndorfer","year":"2025","unstructured":"Hinterndorfer M, Spiteri VA, Ciulli A, Winter GE (2025) Targeted protein degradation for cancer therapy. Nat Rev Cancer. https:\/\/doi.org\/10.1038\/s41568-025-00817-8","journal-title":"Nat Rev Cancer"},{"key":"1603_CR2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI175265","volume":"134","author":"H Yoon","year":"2024","unstructured":"Yoon H, Rutter JC, Li Y-D, Ebert BL (2024) Induced protein degradation for therapeutics: past, present, and future. J Clin Invest 134:e175265. https:\/\/doi.org\/10.1172\/JCI175265","journal-title":"J Clin Invest"},{"key":"1603_CR3","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41580-024-00729-9","volume":"25","author":"JM Tsai","year":"2024","unstructured":"Tsai JM, Nowak RP, Ebert BL, Fischer ES (2024) Targeted protein degradation: from mechanisms to clinic. Nat Rev Mol Cell Biol 25:740\u2013757. https:\/\/doi.org\/10.1038\/s41580-024-00729-9","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1603_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01305-3","volume":"20","author":"R Du","year":"2021","unstructured":"Du R, Huang C, Liu K, Li X, Dong Z (2021) Targeting AURKA in cancer: molecular mechanisms and opportunities for cancer therapy. Mol Cancer 20:15. https:\/\/doi.org\/10.1186\/s12943-020-01305-3","journal-title":"Mol Cancer"},{"key":"1603_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.130913","volume":"265","author":"D Gupta","year":"2024","unstructured":"Gupta D, Kumar M, Saifi S, Rawat S, Ethayathulla AS, Kaur P (2024) A comprehensive review on role of Aurora kinase inhibitors (AKIs) in cancer therapeutics. Int J Biol Macromol 265:130913. https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.130913","journal-title":"Int J Biol Macromol"},{"key":"1603_CR6","doi-asserted-by":"publisher","unstructured":"Grobholz R (2025) [Neuroendocrine differentiation in prostate neoplasms. German version], Pathol. Heidelb. Ger. https:\/\/doi.org\/10.1007\/s00292-025-01447-5.","DOI":"10.1007\/s00292-025-01447-5"},{"key":"1603_CR7","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ccr.2008.12.005","volume":"15","author":"T Otto","year":"2009","unstructured":"Otto T, Horn S, Brockmann M, Eilers U, Sch\u00fcttrumpf L, Popov N, Kenney AM, Schulte JH, Beijersbergen R, Christiansen H, Berwanger B, Eilers M (2009) Stabilization of N-myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell 15:67\u201378. https:\/\/doi.org\/10.1016\/j.ccr.2008.12.005","journal-title":"Cancer Cell"},{"key":"1603_CR8","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.bmcl.2012.10.013","volume":"23","author":"JL Yap","year":"2013","unstructured":"Yap JL, Wang H, Hu A, Chauhan J, Jung K-Y, Gharavi RB, Prochownik EV, Fletcher S (2013) Pharmacophore identification of c-Myc inhibitor 10074\u2013G5. Bioorg Med Chem Lett 23:370\u2013374. https:\/\/doi.org\/10.1016\/j.bmcl.2012.10.013","journal-title":"Bioorg Med Chem Lett"},{"issue":"6","key":"1603_CR9","doi-asserted-by":"publisher","first-page":"936","DOI":"10.18632\/oncotarget.1108","volume":"4","author":"H Wang","year":"2013","unstructured":"Wang H, Chauhan J, Hu A, Pendleton K, Yap JL, Sabato PE, Jones JW, Perri M, Yu J, Cione E, Kane MA (2013) Disruption of Myc-Max heterodimerization with improved cell-penetrating analogs of the small molecule 10074\u2013G5. Oncotarget 4(6):936. https:\/\/doi.org\/10.18632\/oncotarget.1108","journal-title":"Oncotarget"},{"key":"1603_CR10","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1002\/cmdc.201402189","volume":"9","author":"J Chauhan","year":"2014","unstructured":"Chauhan J, Wang H, Yap JL, Sabato PE, Hu A, Prochownik EV, Fletcher S (2014) Discovery of methyl 4\u2019-methyl-5-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-[1,1\u2019-biphenyl]-3-carboxylate, an improved small-molecule inhibitor of c-Myc-max dimerization. ChemMedChem 9:2274\u20132285. https:\/\/doi.org\/10.1002\/cmdc.201402189","journal-title":"ChemMedChem"},{"key":"1603_CR11","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1021\/jm501440q","volume":"58","author":"K-Y Jung","year":"2015","unstructured":"Jung K-Y, Wang H, Teriete P, Yap JL, Chen L, Lanning ME, Hu A, Lambert LJ, Holien T, Sundan A, Cosford NDP, Prochownik EV, Fletcher S (2015) Perturbation of the c-Myc-Max protein-protein interaction via synthetic \u03b1-helix mimetics. J Med Chem 58:3002\u20133024. https:\/\/doi.org\/10.1021\/jm501440q","journal-title":"J Med Chem"},{"key":"1603_CR12","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1021\/acscentsci.2c01317","volume":"9","author":"ES Toriki","year":"2023","unstructured":"Toriki ES, Papatzimas JW, Nishikawa K, Dovala D, Frank AO, Hesse MJ, Dankova D, Song J-G, Bruce-Smythe M, Struble H, Garcia FJ, Brittain SM, Kile AC, McGregor LM, McKenna JM, Tallarico JA, Schirle M, Nomura DK (2023) Rational chemical design of molecular glue degraders. ACS Cent Sci 9:915\u2013926. https:\/\/doi.org\/10.1021\/acscentsci.2c01317","journal-title":"ACS Cent Sci"},{"key":"1603_CR13","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.chembiol.2024.12.006","volume":"32","author":"J Tang","year":"2025","unstructured":"Tang J, Moorthy R, Hirsch LE, Demir \u00d6, Baker ZD, Naumann JA, Jones KFM, Grillo MJ, Haefner ES, Shi K, Levy MJ, Gupta HB, Aihara H, Harris RS, Amaro RE, Levinson NM, Harki DA (2025) Targeting N-Myc in neuroblastoma with selective Aurora kinase A degraders. Cell Chem Biol 32:352-362.e10. https:\/\/doi.org\/10.1016\/j.chembiol.2024.12.006","journal-title":"Cell Chem Biol"},{"key":"1603_CR14","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/s41589-020-00652-y","volume":"16","author":"B Adhikari","year":"2020","unstructured":"Adhikari B, Bozilovic J, Diebold M, Schwarz JD, Hofstetter J, Schr\u00f6der M, Wanior M, Narain A, Vogt M, Dudvarski Stankovic N, Baluapuri A, Sch\u00f6nemann L, Eing L, Bhandare P, Kuster B, Schlosser A, Heinzlmeir S, Sotriffer C, Knapp S, Wolf E (2020) Protac-mediated degradation reveals a non-catalytic function of AURORA-A kinase. Nat Chem Biol 16:1179\u20131188. https:\/\/doi.org\/10.1038\/s41589-020-00652-y","journal-title":"Nat Chem Biol"},{"key":"1603_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16162805","volume":"16","author":"H Liu","year":"2024","unstructured":"Liu H, Cali Daylan AE, Yang J, Tanwar A, Borczuk A, Zhang D, Chau V, Li S, Ge X, Halmos B, Zang X, Cheng H (2024) Aurora kinase A inhibition potentiates platinum and radiation cytotoxicity in non-small-cell lung cancer cells and induces expression of alternative immune checkpoints. Cancers (Basel) 16:2805. https:\/\/doi.org\/10.3390\/cancers16162805","journal-title":"Cancers (Basel)"},{"key":"1603_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02353-3","volume":"24","author":"P Vats","year":"2025","unstructured":"Vats P, Saini C, Baweja B, Srivastava SK, Kumar A, Kushwah AS, Nema R (2025) Aurora kinases signaling in cancer: from molecular perception to targeted therapies. Mol Cancer 24:180. https:\/\/doi.org\/10.1186\/s12943-025-02353-3","journal-title":"Mol Cancer"},{"key":"1603_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14051245","volume":"14","author":"SE Rebuzzi","year":"2022","unstructured":"Rebuzzi SE, Rescigno P, Catalano F, Mollica V, Vogl UM, Marandino L, Massari F, Pereira Mestre R, Zanardi E, Signori A, Buti S, Bauckneht M, Gillessen S, Banna GL, Fornarini G (2022) Immune checkpoint inhibitors in advanced prostate cancer: current data and future perspectives. Cancers (Basel) 14:1245. https:\/\/doi.org\/10.3390\/cancers14051245","journal-title":"Cancers (Basel)"},{"key":"1603_CR18","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41391-021-00340-5","volume":"24","author":"J Stultz","year":"2021","unstructured":"Stultz J, Fong L (2021) How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer. Prostate Cancer Prostatic Dis 24:697\u2013717. https:\/\/doi.org\/10.1038\/s41391-021-00340-5","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1603_CR19","doi-asserted-by":"publisher","DOI":"10.1159\/000541881","author":"R Novysedlak","year":"2024","unstructured":"Novysedlak R, Guney M, Al Khouri M, Bartolini R, Koumbas Foley L, Benesova I, Ozaniak A, Novak V, Vesely S, Pacas P, Buchler T, Ozaniak Strizova Z (2024) The immune microenvironment in prostate cancer: a comprehensive review. Oncology. https:\/\/doi.org\/10.1159\/000541881","journal-title":"Oncology"},{"key":"1603_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217155","volume":"601","author":"D Liu","year":"2024","unstructured":"Liu D, Wang L, Guo Y (2024) Advances in and prospects of immunotherapy for prostate cancer. Cancer Lett 601:217155. https:\/\/doi.org\/10.1016\/j.canlet.2024.217155","journal-title":"Cancer Lett"},{"key":"1603_CR21","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1002\/cac2.12190","volume":"41","author":"S Sun","year":"2021","unstructured":"Sun S, Zhou W, Li X, Peng F, Yan M, Zhan Y, An F, Li X, Liu Y, Liu Q, Piao H (2021) Nuclear aurora kinase A triggers programmed death-ligand 1-mediated immune suppression by activating MYC transcription in triple-negative breast cancer. Cancer Commun 41:851\u2013866. https:\/\/doi.org\/10.1002\/cac2.12190","journal-title":"Cancer Commun"},{"key":"1603_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113495","volume":"221","author":"T Pradhan","year":"2021","unstructured":"Pradhan T, Gupta O, Singh G, Monga V (2021) Aurora kinase inhibitors as potential anticancer agents: recent advances. Eur J Med Chem 221:113495. https:\/\/doi.org\/10.1016\/j.ejmech.2021.113495","journal-title":"Eur J Med Chem"},{"key":"1603_CR23","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2023.2282184","author":"M Chen","year":"2024","unstructured":"Chen M, Zhu H, Li J, Luo D, Zhang J, Liu W, Wang J (2024) Research progress on the relationship between AURKA and tumorigenesis: the neglected nuclear function of AURKA. Ann Med. https:\/\/doi.org\/10.1080\/07853890.2023.2282184","journal-title":"Ann Med"},{"key":"1603_CR24","doi-asserted-by":"publisher","first-page":"6210","DOI":"10.1039\/d2cs00339b","volume":"51","author":"KM Riching","year":"2022","unstructured":"Riching KM, Caine EA, Urh M, Daniels DL (2022) The importance of cellular degradation kinetics for understanding mechanisms in targeted protein degradation. Chem Soc Rev 51:6210\u20136221. https:\/\/doi.org\/10.1039\/d2cs00339b","journal-title":"Chem Soc Rev"},{"key":"1603_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01242-2","author":"M Wu","year":"2022","unstructured":"Wu M, Huang Q, Xie Y, Wu X, Ma H, Zhang Y, Xia Y (2022) Improvement of the anticancer efficacy of PD-1\/PD-L1 blockade via combination therapy and PD-L1 regulation. J Hematol Oncol. https:\/\/doi.org\/10.1186\/s13045-022-01242-2","journal-title":"J Hematol Oncol"},{"key":"1603_CR26","doi-asserted-by":"publisher","first-page":"234","DOI":"10.18632\/oncotarget.2703","volume":"6","author":"JL Bishop","year":"2015","unstructured":"Bishop JL, Sio A, Angeles A, Roberts ME, Azad AA, Chi KN, Zoubeidi A (2015) PD-L1 is highly expressed in Enzalutamide resistant prostate cancer. Oncotarget 6:234\u2013242. https:\/\/doi.org\/10.18632\/oncotarget.2703","journal-title":"Oncotarget"},{"issue":"24","key":"1603_CR27","doi-asserted-by":"publisher","first-page":"00325","DOI":"10.1016\/j.tem.2024.12.003","volume":"S1043\u20132760","author":"L Brea","year":"2025","unstructured":"Brea L, Yu J (2025) Tumor-intrinsic regulators of the immune-cold microenvironment of prostate cancer. Trends Endocrinol Metab TEM S1043\u20132760(24):00325\u201300334. https:\/\/doi.org\/10.1016\/j.tem.2024.12.003","journal-title":"Trends Endocrinol Metab TEM"},{"key":"1603_CR28","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/nejmoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Guti\u00e9rrez E, Rutkowski P, Gogas HJ, Lao CD, De Menezes JJ, Dalle S, Arance A, Grob J-J, Srivastava S, Abaskharoun M, Hamilton M, Keidel S, Simonsen KL, Sobiesk AM, Li B, Hodi FS, Long GV (2022) Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med 386:24\u201334. https:\/\/doi.org\/10.1056\/nejmoa2109970","journal-title":"N Engl J Med"},{"key":"1603_CR29","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1158\/0008-5472.can-06-2272","volume":"67","author":"P Briassouli","year":"2007","unstructured":"Briassouli P, Chan F, Savage K, Reis-Filho JS, Linardopoulos S (2007) Aurora-A regulation of nuclear factor-\u03baB signaling by phosphorylation of I\u03baB\u03b1. Cancer Res 67:1689\u20131695. https:\/\/doi.org\/10.1158\/0008-5472.can-06-2272","journal-title":"Cancer Res"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-026-01603-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-026-01603-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-026-01603-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T12:53:49Z","timestamp":1777294429000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-026-01603-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1603"],"URL":"https:\/\/doi.org\/10.1007\/s10637-026-01603-5","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"8 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"During the preparation of this work, the author(s) used ChatGPT to improve the readability of this text. After using this tool\/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the published article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"AI Statement"}}]}}